Abstract Library

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4060 Interim safety and exploratory efficacy results of a phase 2, randomised, parallel-group study of oral Paltusotine treatment in subjects with carcinoid syndrome

Introduction: Carcinoid Syndrome (CS) is the most common functional NET syndrome. It is characterized by watery diarrhea or cutaneous flushing. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS. Paltusotine has been shown to maintain IGF-1 control at levels similar to injected depot SRLs.

Conference:

Presenting Author:

Authors: Usiskin K, Chauhan A, Mui C, Dillon J, Fan X,

Keywords: oral, paltusotine, carcinoid syndrome, phase II,

#3871 A phase 2, randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose response of paltusotine treatment in patients with carcinoid syndrome

Introduction: While long-acting somatostatin receptor ligands (SRLs) are mainstay treatments for carcinoid syndrome (CS), symptom relief at labelled doses is inadequate for many patients. Paltusotine is a novel oral, nonpeptide, selective somatostatin receptor type 2 agonist. In patients with acromegaly, paltusotine maintains plasma IGF-1 levels in patients switching from long-acting SRLs. Paltusotine was well tolerated in phase 2 acromegaly studies.

Conference:

Presenting Author:

Authors: Chauhan A, Shaheen S, Usiskin K, Odueyungbo A, Mui C,

Keywords: Paltusotine, Phase 2 trial, Somatostatin receptor agonist, Safety, Pharmacokinetics, Carcinoid syndrome,

#3301 Telotristat in the management of carcinoid diarrhoea - Real world experience of patients from an ENETS Centre of Excellence in neuroendocrine tumors

Introduction: Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase-3 clinical trials.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Cianci N

Authors: Khanna A, Cianci N, Shah H, Chauhan J, Pipe M,

Keywords: Telotristat, carcinoid syndrome, somatostatin analogues, neuroendocrine tumor,

#3287 Utilization of next generation sequencing in NET/NEC management and practice patterns: A prospective survey of global NET specialists

Introduction: Next generation sequencing based somatic tumor mutation as well as germline mutation data is being increasingly used in cancer management. Pan tumor type FDA approval for NTRK fusion, intermediated-high tumor mutation burden and MSI high status has paved way for tissue agnostic molecularly targeted therapies. Utilization of NGS in neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is currently unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chauhan A, Munir A, Hernando J, Leeuwaarde R, Zhang P,

Keywords: NGS, NEC, NET,